PMID- 18090459
OWN - NLM
STAT- MEDLINE
DCOM- 20080227
LR  - 20181201
IS  - 1537-162X (Electronic)
IS  - 0362-5664 (Linking)
VI  - 30
IP  - 6
DP  - 2007 Nov-Dec
TI  - Zonisamide for essential tremor.
PG  - 345-9
AB  - OBJECTIVE: The pharmacological therapy for essential tremor (ET) is inadequate, 
      and many patients resort to surgical procedures. Zonisamide is an antiepileptic 
      with several potential mechanisms of action. MATERIALS AND METHODS: We evaluated 
      zonisamide for ET in an open-label pilot trial. The primary efficacy point was 
      the change in the Tremor Study Group rating scale (TSGRS) scores. RESULTS: 
      Twenty-two subjects were enrolled (male, 9; mean age +/- SD, 65.0 +/- 12.6 years; 
      mean duration of ET +/- SD, 25.6 +/- 17.1 years). Six subjects dropped because of 
      either (1) adverse events (AEs) and lack of effect (n = 4) or (2) lack of effect 
      (n = 2). Two were lost to follow-up. Fourteen subjects returned for their 
      complete postmedication evaluation. After 3 months (mean +/- SD, 88 +/- 34 days), 
      the final dose was 200 mg (n = 11), 150 mg (n = 1), 100mg (n = 1), and 12.5 mg (n 
      = 1). The mean Tremor Study Group rating scale scores improved from a mean of 
      28.9 (SD, +/-9.2) to a mean of 21.1 (SD, +/-6.5) (P = 0.02, unpaired t test). 
      Seven subjects (50%) had at least a 25% improvement. Subjectively, however, only 
      4 reported marked or moderate improvement, 3 reported mild improvement, and 7 
      reported no change. Adverse events included decreased concentration/cognition (n 
      = 2), constipation (n = 1), nocturia (n = 1), abdominal pain/diarrhea (n = 1), 
      and sedation (n = 1). CONCLUSIONS: Zonisamide significantly (albeit modestly) 
      improved the TSGRS scores in this small group of medically refractory subjects 
      who completed the evaluation. However, clinical impressions did not improve, and 
      the study was complicated by a large dropout rate caused by subjective lack of 
      efficacy and by AEs.
FAU - Ondo, William G
AU  - Ondo WG
AD  - Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA. 
      wondo@bcm.tmc.edu
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Neuropharmacol
JT  - Clinical neuropharmacology
JID - 7607910
RN  - 0 (Anticonvulsants)
RN  - 0 (Isoxazoles)
RN  - 459384H98V (Zonisamide)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticonvulsants/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation
MH  - Essential Tremor/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Isoxazoles/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Severity of Illness Index
MH  - Zonisamide
EDAT- 2007/12/20 09:00
MHDA- 2008/02/28 09:00
CRDT- 2007/12/20 09:00
PHST- 2007/12/20 09:00 [pubmed]
PHST- 2008/02/28 09:00 [medline]
PHST- 2007/12/20 09:00 [entrez]
AID - 00002826-200711000-00004 [pii]
AID - 10.1097/WNF.0b013e318074dd4f [doi]
PST - ppublish
SO  - Clin Neuropharmacol. 2007 Nov-Dec;30(6):345-9. doi: 10.1097/WNF.0b013e318074dd4f.